Evidence map›Paper›PMID 36072876›Full record

ArticleFrontiers in cardiovascular medicine2022

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease.

So-Ryoung Lee, Jin-Hyung Jung, Eue-Keun Choi, Seung-Woo Lee, Soonil Kwon, Ji-Suck Park, Jeehoon Kang, Kyung-Do Han, Kyung Woo Park, Seil Oh and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

So-Ryoung LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Jin-Hyung JungDepartment of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, South Korea.
Eue-Keun ChoiDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Seung-Woo LeeDepartment of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, South Korea.
Soonil KwonDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Ji-Suck ParkDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Jeehoon KangDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Kyung-Do HanDepartment of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea.
Kyung Woo ParkDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Seil OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Gregory Y H LipDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Seoul National University Hospital · KRCatholic University of Korea · KRAalborg University · DKSoongsil University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To compare the net clinical benefit of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (SAPT) in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) at 1- and 3-year after percutaneous coronary intervention (PCI). Background: It has not been studied whether the net clinical benefit of the antithrombotic treatment options differs depending on the elapsed time from the index PCI. Methods: Using the Korean nationwide claims database, we included AF patients who underwent PCI from 2009 to 2019 and constructed two cohorts: 1- and 3-year after PCI. In each cohort, the baseline characteristics of two groups were balanced using propensity score weighting. Ischemic stroke, myocardial infarction, major bleeding, and composite clinical outcomes were analyzed. Results: Among patients with 1-year after PCI, OAC monotherapy ( Conclusion: Oral anticoagulant monotherapy may be a comparable choice for patients with AF and stable CAD compared to OAC plus SAPT. In patients with stable CAD more than 3-year after index PCI, OAC monotherapy would be a better choice, being associated with less major bleeding and a positive net clinical benefit.

Indexed as

antiplatelet agentantithrombotic therapyatrial fibrillationcoronary artery diseaseoral anticoagulant

Identifiers

PMID36072876
PMCPMC9441665
OpenAlexW4292560174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.